No Association between Dopamine D4 Receptor Gene –521 C/T Polymorphism and Tardive Dyskinesia in Schizophrenia

Tardive dyskinesia (TD) is a long-term adverse effect of antipsychotics. We evaluated whether a candidate functional polymorphism of the dopamine D4 receptor (DRD4) gene is associated with drug-induced TD in 209 Korean schizophrenic patients with TD (n = 83) and without TD (n = 126) who were matched for antipsychotic drug exposure and other relevant variables. There was no significant association of the genotype and allele frequencies determined by the –521 C/T SNP of DRD4 between TD and non-TD patients. In addition, there was no significant difference in terms of total Abnormal Involuntary Movement Scale scores among the 3 genotype groups. Within the limitations imposed by the size of the clinical sample, these findings suggest that the DRD4 –521 C/T SNP does not contribute significantly to the risk for TD.

[1]  G. Chouinard.  Interrelations between psychiatric symptoms and drug-induced movement disorder. , 2006, Journal of psychiatry & neuroscience : JPN.

[2]  B. Lerer,et al.  Genetic susceptibility to tardive dyskinesia among schizophrenia subjects: IV. Role of dopaminergic pathway gene polymorphisms , 2006, Pharmacogenetics and genomics.

[3]  C. Tamminga,et al.  Neuroleptic-induced vacuous chewing movements as an animal model of tardive dyskinesia: a study in three rat strains , 2005, Psychopharmacology.

[4]  A. Serretti,et al.  Tardive dyskinesia and DRD2, DRD3, DRD4, 5-HT2A variants in schizophrenia: an association study with repeated assessment. , 2004, The international journal of neuropsychopharmacology.

[5]  Seung-hyun Kim,et al.  Allelic variants interaction of dopamine receptor D4 polymorphism correlate with personality traits in young Korean female population , 2003, American journal of medical genetics. Part B, Neuropsychiatric genetics : the official publication of the International Society of Psychiatric Genetics.

[6]  E. Tan,et al.  Polymorphisms of dopamine receptors and tardive dyskinesia among Chinese patients with schizophrenia , 2003, American journal of medical genetics. Part B, Neuropsychiatric genetics : the official publication of the International Society of Psychiatric Genetics.

[7]  B. Lerer,et al.  Association of dopaminergic and serotonergic genes with tardive dyskinesia in patients with chronic schizophrenia , 2003, The Pharmacogenomics Journal.

[8]  Fabio Macciardi,et al.  Pharmacogenetics of Tardive Dyskinesia: Combined Analysis of 780 Patients Supports Association with Dopamine D3 Receptor Gene Ser9Gly Polymorphism , 2002, Neuropsychopharmacology.

[9]  Z. Rónai,et al.  Genotyping the ‐521C/T functional polymorphism in the promoter region of dopamine D4 receptor (DRD4) gene , 2001, Electrophoresis.

[10]  Z. Rónai,et al.  Association between Novelty Seeking and the −521 C/T polymorphism in the promoter region of the DRD4 gene , 2001, Molecular Psychiatry.

[11]  T. Held,et al.  Klinische charakteristika von patienten mit tardiven dyskinesien , 2000 .

[12]  P. Sachdev.  The Current Status of Tardive Dyskinesia , 2000, The Australian and New Zealand journal of psychiatry.

[13]  M. Rietschel,et al.  Dopamine D3 receptor variant and tardive dyskinesia , 2000, European Archives of Psychiatry and Clinical Neuroscience.

[14]  M. Rietschel,et al.  [Clinical characteristics of patients with tardive dyskinesias]. , 2000, Fortschritte der Neurologie-Psychiatrie.

[15]  T. Arinami,et al.  Identification of a polymorphism in the promoter region of DRD4associated with the human novelty seeking personality trait , 2000, Molecular Psychiatry.

[16]  T. Arinami,et al.  A genetic polymorphism in the promoter region of DRD4 associated with expression and schizophrenia. , 1999, Biochemical and biophysical research communications.

[17]  B. Lerer,et al.  Genotypic association between the dopamine D3 receptor and tardive dyskinesia in chronic schizophrenia , 1999, Molecular Psychiatry.

[18]  P. Gorwood.  Chapter 2.1.4 Genetic association studies in behavioral neuroscience , 1999 .

[19]  K. Hsiao,et al.  Association of TaqI A polymorphism of dopamine D2 receptor gene and tardive dyskinesia in schizophrenia , 1997, Biological Psychiatry.

[20]  V. Steen,et al.  Dopamine D3-receptor gene variant and susceptibility to tardive dyskinesia in schizophrenic patients , 1997, Molecular Psychiatry.

[21]  H. Meltzer,et al.  An overview of the mechanism of action of clozapine. , 1994, The Journal of clinical psychiatry.

[22]  B. Jones,et al.  Free Radicals and Tardive Dyskinesia , 1990, Canadian journal of psychiatry. Revue canadienne de psychiatrie.

[23]  H. Kazamatsuri,et al.  Smoking and tardive dyskinesia , 1987, Biological Psychiatry.

[24]  S. Lal,et al.  Nicotine exposure and tardive dyskinesia , 1987, Biological Psychiatry.

[25]  S. Kay,et al.  The positive and negative syndrome scale (PANSS) for schizophrenia. , 1987, Schizophrenia bulletin.

[26]  J. Kane,et al.  Research diagnoses for tardive dyskinesia. , 1982, Archives of general psychiatry.

[27]  J. Kane,et al.  Tardive dyskinesia: prevalence and risk factors, 1959 to 1979 , 1982, Archives of general psychiatry.

[28]  R. Yassa,et al.  Familial tardive dyskinesia. , 1981, The American journal of psychiatry.

[29]  K. Fuxe,et al.  Effects of single injections of nicotine on the ascending dopamine pathways in the rat. Evidence for increases of dopamine turnover in the mesostriatal and mesolimbic dopamine neurons. , 1981, Acta physiologica Scandinavica.

[30]  J. Gerlach,et al.  γ-Acetylenic GABA in Tardive Dyskinesia , 1980 .

[31]  R. Baldessarini,et al.  Pathophysiologic basis of tardive dyskinesia. , 1977, Advances in biochemical psychopharmacology.

[32]  J. Gerlach,et al.  Gamma-acetylenic GABA in tardive dyskinesia , 1979, Brain Research Bulletin.